[10] In vitro assessment of various cytochromes P450 and glucuronosyltransferases using the antiarrhythmic propafenone as a probe drug

This publication has 10 references indexed in Scilit:

• The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes
  Pharmacogenetics, 1994
• An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy.
  Circulation, 1994
• Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides
  European Journal of Clinical Pharmacology, 1994
• Identification of propafenone metaboliser phenotype from plasma and urine excretion data
  European Journal of Clinical Pharmacology, 1992
• The Role of Genetically Determined Polymorphic Drug Metabolism in the Beta-Blockade Produced by Propafenone
  New England Journal of Medicine, 1990
• Propafenone
  New England Journal of Medicine, 1990
• In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone
  Clinical Pharmacology & Therapeutics, 1989
• Synthesis of the glucuronide of Carazolol
  Carbohydrate Research, 1988
• Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.
  Circulation, 1987
• Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation
  Gastroenterology, 1983